Cargando…

Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD117) overexpression exhibits potential therapeutic implications

BACKGROUND: HER-2/neu and c-kit (CD117) onco-protein are increasingly being recognized as targets for therapy in solid tumors, but data on their role in malignant melanoma is currently limited. We studied the prevalence of overexpression of HER-2/neu and c-Kit in 202 patients with malignant melanoma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Potti, Anil, Hille, Rachel C, Koch, Michael
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2003
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC280698/ https://www.ncbi.nlm.nih.gov/pubmed/14617373 http://dx.doi.org/10.1186/1477-3163-2-8

Ejemplares similares

HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC)
por: Potti, Anil, et al.
Publicado: (2005)

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.
por: DiGiovanna, M. P., et al.
Publicado: (1996)

HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder
por: Latif, Z, et al.
Publicado: (2003)

TOPOIIα and HER-2/neu overexpression/amplification in Barrett’s oesophagus, dysplasia and adenocarcinoma
por: Rossi, Elisa, et al.
Publicado: (2010)

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma
por: Semiz, Huseyin Salih, et al.
Publicado: (2023)

Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status
por: Brodowicz, T, et al.
Publicado: (2001)

Metaplastic breast carcinomas exhibit EGFR, but not HER2, gene amplification and overexpression: immunohistochemical and chromogenic in situ hybridization analysis
por: Reis-Filho, Jorge S, et al.
Publicado: (2005)

Immunohistochemical expression of CD117/KIT, HER2, and Erβ in schistosomal and non-schistosomal urothelial carcinoma of Egyptian patients
por: Khalifa, Sara E.
Publicado: (2023)

Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer
por: Wu, Yanyuan, et al.
Publicado: (2008)

Prognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer
por: Wang, Di, et al.
Publicado: (2016)

Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore
por: de Lima Lopes, Gilberto
Publicado: (2011)

Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis
por: Patel, Y, et al.
Publicado: (2018)

Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients
por: Zhao, Xiangshan, et al.
Publicado: (2012)

A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer
por: Bussolati, G, et al.
Publicado: (2005)

Correlation of breast cancer risk factors with HER-2/neu protein overexpression according to menopausal and estrogen receptor status
por: Tsakountakis, Nikos, et al.
Publicado: (2005)

High prevalence of HER-2/neu overexpression in female breast cancer among an Iraqi population exposed to depleted uranium
por: AL-Dujaily, Esraa A., et al.
Publicado: (2008)

Inhibition of cell growth by BrMC through inactivation of Akt in HER-2/neu-overexpressing breast cancer cells
por: CAO, XIAO-ZHENG, et al.
Publicado: (2014)

Evaluation of C-ErbB-2 Overexpression and Her-2/neu Gene Copy Number Heterogeneity in Barrett’s Adenocarcinoma
por: Walch, Axel, et al.
Publicado: (2000)

Prognostic Value of Her2/neu Expression in Gastrointestinal Stromal Tumors: Immunohistochemical Study
por: Abd El-Aziz, Ahmed M, et al.
Publicado: (2017)

Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer
por: Tokuda, Y, et al.
Publicado: (1999)

Trastuzumab Mediated T-Cell Response against HER-2/Neu Overexpressing Esophageal Adenocarcinoma Depends on Intact Antigen Processing Machinery
por: Milano, Francesca, et al.
Publicado: (2010)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)
por: Santin, Alessandro D., et al.
Publicado: (2016)

Exploratory investigation of PSCA-protein expression in primary breast cancer patients reveals a link to HER2/neu overexpression
por: Link, Theresa, et al.
Publicado: (2017)

Study of the Relationship between MMP-2 and MMP-9 and Her2/neu Overexpression in Gastric Cancer: Clinico-Pathological Correlations
por: Jafari, Elham, et al.
Publicado: (2021)

KIT (CD117) Expression in Benign and Malignant Sweat Gland Tumors
por: Nishida, Haruto, et al.
Publicado: (2015)

Overexpression of c-kit(CD117), relevant with microvessel density, is an independent survival prognostic factor for patients with HBV-related hepatocellular carcinoma
por: Yan, Weiwei, et al.
Publicado: (2018)

Inhibition of Cell Growth and Induction of Apoptosis by Antrodia camphorata in HER-2/neu-Overexpressing Breast Cancer Cells through the Induction of ROS, Depletion of HER-2/neu, and Disruption of the PI3K/Akt Signaling Pathway
por: Lee, Chuan-Chen, et al.
Publicado: (2012)

Pooled peptides from HER-2/neu-overexpressing primary ovarian tumours induce CTL with potent antitumour responses in vitro and in vivo
por: Gritzapis, A D, et al.
Publicado: (2005)

Overexpression of HER2/neu as a Prognostic Value in Iranian Women With Early Stage Breast Cancer; A Single Institute Study
por: Mirtavoos Mahyari, Hanifeh, et al.
Publicado: (2014)

A New Monoclonal Antibody Demonstrates That Muc4, the Intramembrane Ligand for Erbb2/Her2/Neu, Is Overexpressed in Multiple Carcinomas
por: Zhang, Jin, et al.
Publicado: (2002)

Correlation between HER2/neu protein overexpression on Immunohistochemistry and Fluorescent in Situ Hybridization (FISH) in breast carcinoma: Problems in developing countries
por: Mukhtar, Zubaria, et al.
Publicado: (2023)

Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy
por: Rodrigues, Loreta M, et al.
Publicado: (2012)

HER-2/neu Marker Examination using Immunohistochemical Method in Patients Suffering from Gastric Adenocarcinoma
por: Movagharnejad, Kourosh, et al.
Publicado: (2013)

Cytoplasmic Her2/neu Immunohistochemical Staining in Breast Cancer; From a Molecular Point of View
por: Safaei, Akbar, et al.
Publicado: (2019)

Does HER2/neu overexpression in breast cancer influence adjuvant chemotherapy and hormonal therapy choices by Ontario physicians? A physician survey
por: Myers, J.A., et al.
Publicado: (2006)

Peripheral position of CCND1 and HER-2/neu oncogenes within chromosome territories in esophageal and gastric cancers non-related to amplification and overexpression
por: Bizari, Lucimari, et al.
Publicado: (2009)

Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial
por: Zhou, Fei, et al.
Publicado: (2012)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas
por: Black, Jonathan D, et al.
Publicado: (2015)

CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration
por: Braig, S, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_d2meblg21g6bcuqo73bpg1fd1k